Abstract 1493P
Background
The FAMCARE-P13 is a PREM (Patient Reported Experience Measure) developed to assess the level of satisfaction about care received by advanced cancer patients. This self-compiled questionnaire consists of 13 items, scored on a 5-point Likert scale. The aim of this study was the cultural adaptation of the FAMCARE-P13 questionnaire-Italian version, as well as the evaluation of its psychometric properties in advanced cancer outpatients.
Methods
This monocentric study was conducted from January 2022 to November 2023. The tool has been adapted following the forward-back translation method. After a pre-test version on a sample of 30 patients, the tool was administered monthly, for six months, to outpatients with metastatic cancer. An exploratory descriptive and a confirmatory factor (CFA) analyses were conducted to evaluate the presence of underlying components, explained by the 13 items. The Comparative Fit Index and the Tucker-Lewis Index were used as goodness-of-fit indices. For assess the reliability of these indices, the residual root mean square value of approximation was used. The internal consistency was determined by calculating Cronbach's αcoefficient. To evaluate the reliability over time, a test-retest was administered to 30 patients; the global intra-class correlation coefficient (ICC) and the ICC for each item were calculated on these data. The significance level was set at. 05.
Results
The Italian translation was judged valid by translators and reviewers. A total of 319 patients have been enrolled: 59.5% of them declared themselves very satisfied, 37.9% were satisfied and 2.6% responded with the uncertain/very dissatisfied/dissatisfied to the different items. The CFA shows that the Italian version of the tool had a one-factor structure with CFI and TLI of. 92 and. 90 respectively, and RMSEA=. 10 (.12 -. 08). The satisfaction was closely related to the items of doctors' availability and caregiver participation. Cronbach's αwas >. 93 (.90 -. 95), showing satisfactory internal consistency. Even over time the test-retest analysis showed a stability, with a global ICC of 0.607 (p-value <0.0001).
Conclusions
The Italian version of the FAMCARE-P13 is a valid instrument to assess the level of satisfaction about care received by patients with advanced cancer.
Clinical trial identification
NCT04936568.
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
Funding
Research funded by Ministero della Salute (Italy).
Disclosure
E. Zecca: Other, Invited Speaker: Amgen. A.T. Caraceni: Other, Invited Speaker: Angelini, Molteni, Pfizer, Eli Lilly, Kyowa Kirin, Shionogi. All other authors have declared no conflicts of interest.
Resources from the same session
1584P - Association of travel burden (TB) with colorectal cancer (CRC) outcomes in resource-limited settings (RLS)
Presenter: Saquib Banday
Session: Poster session 10
1585P - Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
Presenter: Giovanni Maria Iannantuono
Session: Poster session 10
1586P - Current status of breast cancer: A comparative analysis between developed and developing countries
Presenter: Ana Isabel Martin Quesada
Session: Poster session 10
1587P - As seen through Hollywood’s lens: Cancer in movies, 2010-2020
Presenter: David Benjamin
Session: Poster session 10
1588P - Interventions to improve Herpes Zoster (HZ) vaccination rate among cancer outpatients receiving systemic treatments: A single-center real-world experience
Presenter: Sara Di Bella
Session: Poster session 10
1589P - Ramping up phase I trial recruitment: Defining potential barriers and disparities
Presenter: Burak Aktas
Session: Poster session 10
1590P - Prevalence and impact on survival of presentation to the emergency room of cancer patients: A retrospective study on real-life data
Presenter: Sonia Priou
Session: Poster session 10
1591P - Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024
Presenter: Geetin Majhail
Session: Poster session 10
1592P - Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey
Presenter: Berna C. Özdemir
Session: Poster session 10
1593P - Factors associated with multiple general practitioner consultations before cancer diagnosis in adolescents and young adults: A cohort study in Australia
Presenter: Jeremy Lewin
Session: Poster session 10